Author

Janne-Merete Torset Øien

Observed names: Janne T. Øien, Janne-Merete T. Oien

Institution: Helse Førde

Observed institutions: Oslo University Hospital, Western Norway University of Applied Sciences, Helse Førde

ORCID: 0009-0007-0752-8819

Observed ORCID: 0009-0007-0752-8819

OpenAlex ID: A5085238704

Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate

2017 · Anne Hansen Ree, Hege G. Russnes, et al. · ESMO Open · 39

Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial

2017 · Ida S. Frøysnes, Yvonne Andersson, et al. · Annals of Surgical Oncology · 35

ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis

2019 · Ida S. Frøysnes, Yvonne Andersson, et al. · European Journal of Surgical Oncology · 25

Measuring health-related quality of life: a qualitative study of mental health patients’ experiences of impacts of mental health issues

2025 · Yeujin Ki, Andrew Athan Mcaleavey, et al. · International Journal of Qualitative Studies on Health and Well-Being · 11

Deterioration in mental health: towards a conceptualization based on patients’ perspectives

2026 · Janne Låver, Andrew Athan McAleavey, et al. · International Journal of Qualitative Studies on Health and Well-Being · 1

Using a modified Delphi approach to develop and validate a digital self-management support checklist in bariatric surgery aftercare

2025 · Janne-Merete Torset Øien, John Roger Andersen, et al. · BMJ Open

Abstract CT094: Novel treatment with intraperitoneal MOC31PE immunotoxin in colorectal peritoneal metastasis: Long-term outcome from the ImmunoPeCa phase I/II trial

2018 · Ida S. Froysnes, Yvonne Andersson, et al. · Cancer Research

Works count: 7

Citation count: 111

H-index: 4

I10-index: 4